[Results of the treatment of Sjögren's syndrome with TFX (thymus factor X)].
Seven patients with Sjögren's syndrome (6 with primary and 1 with secondary form of the syndrome developing during SLE) were treated with TFX Polfa in ampoules of 10 mg during 6-12 month. Before the treatment, besides evaluation of the general clinical condition, the following immunological parameters were determined: IgG, IgA and IgM levels, absolute lymphocyte count, T-cell and B-cell counts, absolute neutrophil count, antinuclear antibodies, circulating immune complexes and skin tests with recall antigens (tuberculin and distreptase). The clinical condition of the patients was determined at monthly intervals and the immunological investigations were repeated after the treatment which lasted 6-12 months. In all patients alleviation was observed of the clinical manifestations of the disease with decreased proneness to infections. In some patients improvement was observed of the determined immunological parameters, in the first place, reversal of cutaneous tests from negative to positive.
Fiedorowicz-Fabrycy
I
I
Kliniki Hematologii Instytutu Chorób Wewnetrznych PAM, Szczecinie.
Kordecka
E
E
Ostanek
L
L
D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D000936:Antigen-Antibody Complex / Q000032:analysis; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D007105:Immune Complex Diseases / Q000188:drug therapy* / Q000276:immunology; D007136:Immunoglobulins / Q000032:analysis / Q000187:drug effects; D007279:Injections, Subcutaneous; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D013949:Thymus Extracts / Q000008:administration & dosage* / Q000276:immunology; D013997:Time Factors
D000974:Antibodies, Antinuclear; D000936:Antigen-Antibody Complex; D007136:Immunoglobulins; C019108:TFX; D013949:Thymus Extracts
Ocena wyników leczenia preparatem TFX (thymus factor X) u chorych z zespołem Sjögrena.